TICKERNERD
Menu
ALNYALNYHealthcare · Biotechnology

ALNY Stock Forecast: Alnylam Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$174
−25.13% on the day

The 30 Wall Street analysts covering Alnylam Pharmaceuticals, Inc. hold a median 12-month price target of $350 — +101.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 28 Oct 2026 — in the upper half.

Market cap
$31.1B
Ticker Nerd rank
52/ 100
Median analyst target
$350
Analysts covering
30
Revenue$1.3B+66.9% y/y
Operating income$231.4M
Net income$164.5M
Free cash flow$292.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−23.4%
1M
−31.5%
YTD
−56.2%
1Y
−63.9%
From 52W high
−63.9%
From 52W low
0.0%
$174
$482
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALNY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alnylam Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
52/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
98
Value
97
Growth
96
Quality
94
Revisions
39
Accruals
29
Issuance
27
Momentum
15
Size
7

Volatility (98): The share price has been relatively steady.

Momentum (15): The shares have been drifting down relative to others.

Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ALNY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALNY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$200$300$400$500$600Jan 26Apr 26Jul 26Oct 26ALNYHigh $536Median $350Low $250

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says30 analysts
23 Buy7 Hold0 Sell
Low $250Median $350High $536

The green dot is the last close — the median target sits +101.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 8 moved it down.

DateFirmActionRatingTarget
15 Oct 2026UBSAssumesBuy$550 → $354
14 Oct 2026CitigroupMaintainsBuy$340 → $320
14 Oct 2026Wells FargoMaintainsEqual-Weight$256 → $253
8 Oct 2026RBC CapitalMaintainsOutperform$350 → $345
30 Sept 2026JP MorganMaintainsOverweight$375 → $369
30 Sept 2026JP MorganMaintainsOverweight—
21 Sept 2026HC Wainwright & Co.ReiteratesBuy—
21 Sept 2026HC Wainwright & Co.ReiteratesBuy$455
8 Sept 2026JefferiesMaintainsHold—
8 Sept 2026JefferiesMaintainsHold$230 → $260
2 Sept 2026HC Wainwright & Co.ReiteratesBuy—
2 Sept 2026HC Wainwright & Co.ReiteratesBuy$455
19 Aug 2026BMO CapitalInitiatesOutperform$318
19 Aug 2026BMO CapitalInitiatesOutperform—
14 Aug 2026Wells FargoMaintainsEqual-Weight—
14 Aug 2026Wells FargoMaintainsEqual-Weight$316 → $256
4 Aug 2026HC Wainwright & Co.MaintainsBuy—
4 Aug 2026HC Wainwright & Co.MaintainsBuy$485 → $455
4 Aug 2026Truist SecuritiesMaintainsBuy—
4 Aug 2026Truist SecuritiesMaintainsBuy$410 → $315

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ALNY appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ALNY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Alnylam Pharmaceuticals, Inc. returned −63.9% against +13.6% for the S&P 500, dividends included.

ALNY vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26ALNYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ALNY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−6.3%
Analysts raising
0
Analysts cutting
2
Fundamentals

Alnylam Pharmaceuticals, Inc. (ALNY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
38.2×

Cheaper than 20% of US stocks

Price / sales
6.5×

Cheaper than 19% of US stocks

Price / book
23.0×

Cheaper than 4% of US stocks

EV / EBITDA
29.2×

Cheaper than 9% of US stocks

Growth & margins
Revenue growth (YoY)
66.9%

Higher than 89% of US stocks

Earnings growth (YoY)
66.9%

Higher than 79% of US stocks

Gross margin
76.9%

Higher than 89% of US stocks

Operating margin
17.9%

Higher than 76% of US stocks

Net margin
16.1%

Higher than 79% of US stocks

Returns & dividend
Return on equity
96.6%

Higher than 96% of US stocks

Return on assets
12.3%

Higher than 95% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Alnylam Pharmaceuticals, Inc. (ALNY) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Alnylam Pharmaceuticals, Inc. has a market value of $31.1B and an enterprise value of $30.8B.

  • Revenue in the twelve months to 30 June 2026: $4.8B. The latest quarter grew 66.9% year on year.

  • Net income over the same four quarters: $808.0M, a 16.8% net margin.

  • Diluted earnings per share, trailing twelve months: $5.38.

  • Free cash flow in the twelve months to 30 June 2026: $819.9M.

  • Shares outstanding: 133.7M.

  • Trailing P/E: 38.2×; forward P/E: 18.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Alnylam Pharmaceuticals, Inc. employs 2,500 people — $1.9M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 29 Oct 2026

Data provided by Twelve Data

Peers

ALNY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ALNYAlnylam Pharmaceuticals, Inc.$31.1B52
ROIVRoivant Sciences Ltd.$26.6B36
RPRXRoyalty Pharma Plc$37.3B86
RVMDRevolution Medicines, Inc.$39.4B49
INCYIncyte Corp.$23.3B88
INSMInsmed, Inc.$21.2B77
EXELExelixis, Inc.$17.2B98

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Alnylam Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALNY news & analysis

Lost Money on Alnylam Pharmaceuticals, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Continues Investigating Possible Securities Fraud After 28.31% Share Price Drop

GlobeNewsWire · 29 Oct 2026negative

Glancy Prongay Wolke & Rotter LLP says it is continuing an investigation into possible securities fraud involving Alnylam Pharmaceuticals after a July 30, 2026 disclosure. The headline reports a 28.31% share-price drop and says investors who lost money may have claims to recover losses.

Why it matters — The investigation and reported share-price decline may be relevant to ALNY watchers assessing legal and market developments.

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2026 Earnings Call Transcript

Seeking Alpha · 29 Oct 2026neutral

Seeking Alpha published a transcript of Alnylam Pharmaceuticals’ Q3 2026 earnings call. The provided excerpt contains no further details about the call.

Why it matters — The transcript may be relevant to ALNY watchers seeking the company’s commentary, but the excerpt does not specify its contents.

Alnylam Pharmaceuticals Q3 Earnings Call Highlights

MarketBeat · 29 Oct 2026positive

Alnylam reported Q3 2026 global net product revenue of approximately $1.3 billion, up 52% year over year and 10% sequentially. Continued growth in its transthyretin (TTR) franchise drove results.

Why it matters — ALNY watchers may note the reported revenue growth and the TTR franchise's contribution to it.

Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates

Zacks Investment Research · 29 Oct 2026positive

Alnylam Pharmaceuticals reported quarterly earnings of $16.26 per share, above the Zacks Consensus Estimate of $2.19. Earnings were $2.90 per share in the year-ago quarter.

Why it matters — The report gives ALNY watchers a comparison of quarterly earnings with analyst expectations and the prior-year quarter.

Compared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key Metrics

Zacks Investment Research · 29 Oct 2026neutral

The item says Alnylam’s Q3 headline results for the quarter ended September 2026 provide one view of performance, and focuses on comparing key metrics with Wall Street estimates and year-ago values. The excerpt does not provide the metrics or comparison outcomes.

Why it matters — ALNY watchers may find the metric comparisons useful for assessing quarterly performance beyond the top and bottom lines, though the excerpt gives no specific results.

FAQ

Frequently asked questions about ALNY stock

What is the ALNY stock price forecast for 2026-2027?

The 30 Wall Street analysts covering Alnylam Pharmaceuticals, Inc. have a median 12-month price target of $350, with estimates ranging from $250 to $536. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALNY stock a buy right now?

Of the 30 analysts covering Alnylam Pharmaceuticals, Inc., 23 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alnylam Pharmaceuticals, Inc. 52 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALNY?

As at 28 Oct 2026, Alnylam Pharmaceuticals, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).

Will ALNY stock go up?

No one can know that. What the data says: the median 12-month target from 30 analysts implies +101.1% from the last close, and Ticker Nerd's factor model ranks Alnylam Pharmaceuticals, Inc. 52 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALNY stock forecast for 2030?

No analyst covering Alnylam Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALNY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $250 to $536 over the next 12 months.

How has ALNY stock performed over the past year?

Alnylam Pharmaceuticals, Inc. returned -63.9% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Alnylam Pharmaceuticals, Inc. do?

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on RNA interference therapeutics.

What is the latest news on ALNY?

The most recent item we track (GlobeNewsWire, 29 Oct 2026): "Lost Money on Alnylam Pharmaceuticals, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Continues Investigating Possible Securities Fraud After 28.31% Share Price Drop". Glancy Prongay Wolke & Rotter LLP says it is continuing an investigation into possible securities fraud involving Alnylam Pharmaceuticals after a July 30, 2026 disclosure. The headline reports a 28.31% share-price drop and says investors who lost money may have claims to recover losses.

Company

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on RNA interference therapeutics. Alnylam Pharmaceuticals develops, manufactures, and commercializes medicines designed to silence disease-causing genes, with a primary emphasis on rare genetic and cardiometabolic conditions. Its current portfolio includes approved therapies for transthyretin-mediated amyloidosis, and the company also advances programs in areas such as hypertension and other genetically defined diseases. Alnylam Pharmaceuticals works across the United States, Europe, and other international markets, supporting patients through specialized treatments and healthcare partnerships. Headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals plays a significant role in the growing RNAi medicine segment, where it is recognized for translating gene-silencing science into commercial therapies for serious conditions.

CEO Dr. Yvonne L. Greenstreet M.B.A., M.D. · 2,500 employees · United States · https://www.alnylam.com